Woojin B&G, a bio-specialized company in veterinary pharmaceuticals, announced on October 23 that it has obtained product approval from the Ministry of Food and Drug Safety for its human-use active pharmaceutical ingredient, "Lactobacillus sporogenes lyophilized culture."
This product will be used as a raw material for probiotics (live bacterial preparations) that are utilized in the treatment of gastrointestinal disorders.
Lactobacillus sporogenes is a strain with excellent heat and acid resistance, allowing it to survive and colonize stably in the intestines. It helps improve the balance of intestinal microbiota, supports digestive health, alleviates diarrhea, and enhances the intestinal environment.
With this approval, Woojin B&G becomes one of only two companies in Korea licensed to manufacture raw pharmaceutical ingredients based on this strain. By localizing the production of an ingredient that had previously relied mainly on imports, the company has secured both supply stability and price competitiveness.
The domestic market for raw materials based on this strain is estimated to be worth approximately 3 billion KRW, and there is anticipated demand for stable sourcing by Korean pharmaceutical companies, along with the effect of import substitution.
Furthermore, this approval marks another case of Woojin B&G expanding its specialized microbial cultivation and lyophilization technology into the field of human-use active pharmaceutical ingredients.
A Woojin B&G representative stated, "This product approval demonstrates that our microbial cultivation and formulation technology is recognized as competitive in the human-use raw material sector. We will continue to expand our collaboration base with domestic and global pharmaceutical companies through ongoing research and development and quality enhancement."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
